Edited by: Ksenija Bogoeva-Kostovska

Surabava, Indonesia

E-mail: muhammad-v-a@fk.unair.ac.id

Edited by: Ksenija Bogoeva-Kostovska Citation: Simamora RM, Arfijanto MV, Rusil M, Utomo B, Pakpahan C, Adi GP. Clinical Signs and Laboratory Parameters as Predictors of Mortality Among Hospitalized Human Immunodeficiency Virus-Infected Adult Patients at Tertiary Hospital in Surabaya. Open Access Maced J Med Sci. 2021 Jun 25; 9(B):497-502.

https://doi.org/10.3889/oamjms.2021.6223 Keywords: Predictors: Morbidity: Mortality: Human

Immunodeficiency Virus/AIDS; Clinical sign; Laboratory *Correspondence: Muhammad Vitanata Arfijanto, Department of Internal Medicine, Faculty of Medicine, tomo General Tacobine Unacit

Soetomo General Teaching Hospital, Airlangga University,

E-mail: muhammad-v-a@tk.unair.ac.u Received: 18-May-2021 Revised: 10-Jun-2021 Accepted: 15-Jun-2021 Copyright: © 2021 Rentha Monica Simamora, Muhammad Vitanata Arfijanto, Musofa Rusli, Budi Utomo, Cennikon Pakpahan, Garry Prasetyo Adi

Funding: This research did not receive any financial support Competing Interest: The authors have declared that no

Competing Interest: the adultors have declared that ho competing interest exists Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)





Clinical Signs and Laboratory Parameters as Predictors of Mortality among Hospitalized Human Immunodeficiency Virus-Infected Adult Patients at Tertiary Hospital in Surabaya

Rentha Monica Simamora^{1,2}, Muhammad Vitanata Arfijanto¹*, Musofa Rusli¹, Budi Utomo³, Cennikon Pakpahan⁴, Garry Prasetvo Adi¹

¹Department of Internal Medicine, Faculty of Medicine, Airlangga University, Soetomo General Teaching Hospital, Surabaya, Indonesia; ²Department of Internal Medicine, Dr. Kanudjoso Djatiwibowo General Hospital, Balikpapan, Indonesia; ³Department of Public Health and Preventive Medicine. Faculty of Medicine. Airlangga University. Surabaya. Indonesia: ⁴Department of Biomedical Sciences, Andrology Study Program, Faculty of Medicine, Airlangga University, Surabaya, Indonesia

Abstract

BACKGROUND: The morbidity and mortality rates due to human immunodeficiency virus (HIV) infection are still high despite various and advanced efforts in the management given for HIV/AIDS patients

AIM: This study proposed that clinical signs and laboratory parameters could be expected to predict the patient's mortality.

METHODS: This retrospective study was done by collecting 408 medical records of adult HIV/AIDS inpatients at a tertiary hospital in Surabaya from January 1, 2017, to December 31, 2019. Bivariate analysis using Chi-square test was carried out on nine variables, which were Glasgow Coma Scale (GCS) <15, hypotension, PaO,/FiO, <400 mmHg, elevated liver enzymes, hemoglobin levels <10 mg/dl, platelet count <150,000/mm³, eGFR <60 ml/min/1.73 m², albumin levels <3.5 mg/dl, and body mass index (BMI) <18.5 kg/m². Variables which met the criteria would be included in the multivariate analysis using logistic regression.

RESULTS: Based on bivariate analysis, mortality was found to be significantly associated with GCS <15, hypotension, PaO₂/FiO₂, elevated liver enzymes, platelet count <100,000 mm³, eGFR <60 ml/1.73kg/m², albumin levels <3.5 mgdl, and BMI <18.5 kg/m². However, based on multivariate analysis, there were five variables which were found to be able to independently predict the patients' mortality, those were GCS <15 (OR 11.625), hypotension (OR 6.062), PaO,/FiO,<400 mmHg (OR 7.794), eGFR <60 ml/min/1.73 m² (OR 2.646), and albumin levels <3.5 mg/dl (OR 4.091).

CONCLUSION: GCS <15, hypotension, PaO₂/FiO₂ <400 mmHg, eGFR <60 ml/1.73g/m², and albumin levels <3.5 mg/dl were found as the independent risk factors which could predict the hospitalized HIV/AIDS patients' mortality

Introduction

Human immunodeficiency virus (HIV) is a retrovirus that attacks human immune cells, especially CD4 T cells, resulting the decreasing of the number of CD4 T cells which then can cause the weakening of body's immune system [1]. HIV can directly damage body's tissues and organs through an inflammatory process that causes organ dysfunction and leads to mortality. Heretofore, HIV/ AIDS has been becoming a global health problem with a high mortality rate and increasing number of sufferers every year [2], [3].

There have been various studies conducted to deepen the understanding of the characteristics and predictor factors of HIV-infected adult people's mortality. Some mortality predictors reported were platelets, glomerular filtration rate, liver function, serum albumin, CD4 values, and body mass index (BMI) [4], [5], [6]. The previous retrospective and prospective studies showed a variety of data relating to the characteristics of the research subject, socioeconomic conditions, and the length of the study conducted [7], [8], [9], [10].

Studies discussing about predictors of mortality among HIV/AIDS patients in Indonesia are still limited, whereas knowing the characteristics and factors that influence mortality is very important to improve medical interventions for HIV/AIDS patients. Therefore, this study was aimed to determine the characteristics and factors that could predict the HIV/ AIDS patients' mortality using simple parameters through clinical signs and laboratory examinations that have been routinely carried out since the beginning of the patient hospitalization.

Open Access Maced J Med Sci. 2021 Jun 25; 9(B):497-502

Methods

Results

Study design and population

This research was conducted at a tertiary referral hospital in Surabava, the capital of the province of East Java which has the highest number of HIV/AIDS sufferers in Indonesia. This study was a retrospective study done by collecting the medical record data which was obtained using systematic sampling from January 1, 2017, to December 31, 2019. The inclusion criteria included medical record of men and women inpatients aged ≥18 years who have been diagnosed with HIV/AIDS. The HIV/AIDS diagnosis was obtained from the ICD coding listed on the medical resume. Some data which were excluded in this study were including medical records of HIV/AIDS patients who discharged at their own request, patients who had traumatic brain injury, patients who had organ dysfunction before being diagnosed with HIV/AIDS, patients who had hematological disorders before being diagnosed with HIV/AIDS, patients diagnosed with cancer that was not related to HIV/AIDS, the pregnant patients, the missing data, the incomplete data, as well as the corrupt data.

Data collection

The data were collected using a data recording form which contained the characteristics and variables of the research. Characteristics of the research's subjects were in the form of demographic and clinical data. The demographic data included the patient's age, gender, place of residence, marital status, education level, HIV risk factors, and length of the hospital stay. Moreover, the clinical data included HIV clinical stage according to the WHO, ART therapy status, Glasgow Coma Scale (GCS), PaO₂/FiO₂ ratio, blood pressure, SGOT level, SGPT level, creatinine level, glomerular filtration rate, hemoglobin level, platelet count, serum albumin level, and BMI.

The independent variables in this study were GCS <15, hypotension, PaO₂/FiO₂ <400 mmHg, elevated liver enzymes, hemoglobin levels <10 mg/dl, platelet counts <150.000/mm³, eGFR <60 ml/min/1.73 m², albumin levels <3.5 mg/dl, and BMI <18.5 kg/m². Hypotension was defined as systolic blood pressure <100 mmHg or diastolic blood pressure <60 mmHg. Elevated liver enzymes were defined as SGOT levels with values above 50 µ/L or SGPT levels with values above 70 μ /L [11]. This study used the CKD-EPI formula for the glomerular filtration rate. Many studies suggested that the CKD-EPI formula was more preferable than MDRD and CG for calculating the glomerular filtration rate in the HIV patient population. The CKD-EPI formula did not require any information regarding body weight, unlike CG which used to bias the results of glomerular filtration rate [10], [12], [13].

In this study, most of the HIV/AIDS patients hospitalized were male with a total of 274 people (67.2%). Furthermore, the female patients were 134 people or 32.8% of total data gained. In terms of age, it was found that the age ranged from 19 years old for the youngest to 70 years old for the eldest. Moreover, data of the patients' marital status were recorded as followed: 204 patients (50%) were married, 158 patients (38.7%) were single, and 46 patients (11.3%) were widowers or widows. In addition, most of the patients, which were 87.5% of total data or 357 patients to be exact, had high school education background.

The average length of HIV/AIDS patient's the hospital stay in this study was 4 days, with 1 day for the shortest treatment duration and 54 days for the longest one. In terms of transmission risk factors, there were 81 patients (19.8%) heterosexual risk, which was the highest risk factor in this study according to the data which has been collected. Most of the patients, specifically 390 patients (95.6%) were domiciled in Surabaya, while only 18 patients (4.4%) were domiciled outside Surabaya. Based on further data from 408 patients who underwent the treatment, it was known that the mortality rate was 31.1% (127/408).

The clinical characteristics used in this study included ART therapy status, the WHO clinical stage, GCS, PaO_2/FiO_2 ratio, systolic and diastolic blood pressure, eGFR, SGOT, SGPT, hemoglobin, platelets, albumin, and BMI. These clinical characteristics are shown in Table 1.

From the medical record data collected, it was known that 207 patients (50.7%) were on ART therapy, 173 patients (42.4%) had never received ART treatment, and 28 patients (6.9%) stopped taking ART treatment. Most of the subjects in this study, as many as 299 patients (73.3%), were at Stage 4 based on the WHO clinical stage. A total of 322 patients (78.9%) had a GCS of 15. The data of PaO₂/FiO₂ ratio showed the ratio value of ≥400 in 286 patients (70.1%) and <400 in 122 patients (29.9%). As many as 322 patients (78.9%) had systolic blood pressure of ≥100 mmHg. Moreover, most of the patients had diastolic blood pressure of ≥60 mmHg, while 46 patients (11.3%) had diastolic blood pressure below 60 mmHg.

Based on the obtained data, there were 312 patients (76.5%) who had eGFR \geq 60 ml/min/1.73 m². The AST data showed that 199 patients (48.8%) had AST \leq 50 μ /L, which was almost the same as those with AST >50 μ /L, specifically 209 patients (51.2%). The SGPT data reported that most patients had SGPT values \leq 70 μ /L, specifically 332 patients (81.4%). As for the hemoglobin data, there was no significant difference between the ones who had Hb \geq 10 mg/dl and the ones

Characteristics n % Result ART therapy status 173 42.4 Receiving ART 207 50.7 Loss to follow-up 28 6.9 WHO clinical stage 5 5 Stage 1 0 0 0 5 5 5 6.9 WHO clinical stage 0 0 0 5 5 5 6.7 5 5 5 6 7 5 5 7 5 5 6 5 7 5 5 6 5 7 5 3 7 5 5 6 5 7 5 5 6 5 7 5 6 5 7 5 6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 5 5 5 5 5 5 5 5 5 5	Table 1: Clinical characteristics						
ART therapy status 173 42.4 Receiving ART 207 50.7 Loss to follow-up 28 6.9 WHO clinical stage 0 0 Stage 1 0 0 Stage 2 0 0 Stage 3 109 26,7 Stage 4 299 73,3 GCS 6CS 6CS GCS 322 78.9 GCS 70.1 PaO_/FIO_2 PaO_/FIO_2<400 122 29.9 Systolic blood pressure 21.1 PaO_/FIO_2<400 122 29.9 Systolic blood pressure 21.1 Diastolic blood pressure 21.1 Diastolic blood pressure 260 mmHg 86 260 mmHg 362 88.7 <60 mmHg 46 11.3 eGFR <60 ml/menit/1.73 m ² 312 76.5 eGFR <60 ml/menit/1.73 m ² 96 23.5 SGOT SGOT >50 μ/L 209 51.2 SGPT SGPT <70 μ/L 32 81.4 SGPT <70 μ/L <	Characteristics	n	%	Result			
Naive 173 42.4 Receiving ART 207 50.7 Loss to follow-up 28 6.9 WHO clinical stage 5 5 Stage 1 0 0 0 Stage 2 0 0 0 Stage 3 109 26,7 5 Stage 4 299 73,3 GCS GCS =15 322 78.9 GCS GCS <15	ART therapy status			÷			
Receiving ART 207 50.7 Loss to follow-up 28 6.9 WHO clinical stage 0 0 Stage 1 0 0 Stage 2 0 0 Stage 3 109 26,7 Stage 4 299 73,3 GCS 109 26,7 GCS 515 86 21.1 PaO_/FiO_2 78.9 78.9 PaO_/FiO_2 286 70.1 PaO_/FiO_2 29.9 322 Systolic blood pressure 2100 286 ≥100 mmHg 322 78.9 <100 mmHg	Naive	173	42.4				
Loss to follow-up 28 6.9 WHO clinical stage Stage 1 0 0 Stage 2 0 0 Stage 3 109 26,7 Stage 4 299 73,3 GCS GCS =15 322 78.9 GCS <15 86 21.1 PaO_/FIO_ PaO_/FIO_2400 286 70.1 PaO_/FIO_2400 122 29.9 Systolic blood pressure ≥100 mmHg 322 78.9 <100 mmHg 86 21.1 Diastolic blood pressure ≥60 mmHg 362 88.7 <60 mmHg 46 11.3 eGFR eGFR <60 ml/menit/1.73 m ² 96 23.5 SGOT SGOT 50 µ/L 199 48.8 SGOT >50 µ/L 209 51.2 SGPT <70 µ/L 332 81.4 SGPT >70 µ/L 332 81.4 SGPT >70 µ/L 76 18.6 Hemoglobin Hb ≥10 mg/dl 202 49.5 Platelet count ≥150,000/mm ³ 233 79.2 <150,000/mm ³ 85 20.6 Albumin levels	Receiving ART	207	50.7				
WHO clinical stage 0 0 Stage 1 0 0 Stage 2 0 0 Stage 3 109 26,7 Stage 4 299 73,3 GCS	Loss to follow-up	28	6.9				
Stage 1 0 0 Stage 2 0 0 Stage 3 109 26,7 Stage 4 299 73,3 GCS 5 322 78.9 GCS <15	WHO clinical stage						
Stage 2 0 0 Stage 3 109 26,7 Stage 4 299 73,3 GCS 299 73,3 GCS 322 78.9 GCS <15	Stage 1	0	0				
Stage 3 109 26,7 Stage 4 299 73,3 GCS	Stage 2	0	0				
Stage 4 299 73,3 GCS	Stage 3	109	26.7				
GCS 322 78.9 GCS <15	Stage 4	299	73.3				
GCS =15 322 78.9 GCS <15	GCS		- / -				
GCS <15	GCS =15	322	78.9				
PaO/FiO2 PaO/FiO2 ≥ 400 286 70.1 PaO/FiO2 ≥ 400 122 29.9 Systolic blood pressure ≥ 2100 mmHg 322 78.9 <100 mmHg	GCS <15	86	21.1				
PaO_/FIO_≥400 286 70.1 PaO_/FIO_≥400 122 29.9 Systolic blood pressure 2100 mmHg 322 78.9 <100 mmHg	PaQ./FiQ.						
PaO ₂ /FiO ₂ <400	PaO./FiO.≥400	286	70.1				
Systolic blood pressure ≥100 mmHg 322 78.9 <100 mmHg 86 21.1 Diastolic blood pressure ≥60 mmHg 362 88.7 <60 mmHg 46 11.3 eGFR eGFR 500 ml/menit/1.73 m ² 312 76.5 eGFR 60 ml/menit/1.73 m ² 96 23.5 SGOT SGOT 50 μ /L 199 48.8 SGOT 50 μ /L 209 51.2 SGPT SGPT 570 μ /L 332 81.4 SGPT 570 μ /L 76 18.6 Hemoglobin Hb ≥10 mg/dl 206 50.5 Hb <10 mg/dl 202 49.5 Platelet count ≥150,000/mm ³ 323 79.2 <150,000/mm ³ 85 20.6 Albumin levels	PaO /FiO <400	122	29.9				
≥100 mmHg 322 78.9 <100 mmHg	Systolic blood pressure						
<100 mmHg	≥100 mmHg	322	78.9				
Diastolic blood pressure 260 mmHg 362 88.7 <60 mmHg	<100 mmHg	86	21.1				
≥60 mmHg 362 88.7 ≤60 mmHg 46 11.3 eGFR 11.3 eGFR ≥60 ml/menit/1.73 m ² 312 76.5 eGFR ≤60 ml/menit/1.73 m ² 96 23.5 SGOT 209 51.2 SGPT ≤70 µ/L 332 81.4 SGPT ≤70 µ/L 76 18.6 Hemoglobin Hb ≥10 mg/dl 202 49.5 Platelet count ≥150,000/mm ³ 323 79.2 <150,000/mm ³ 85 20.6 Albumin levels >0 5 me/dt 154 37.7 37.7	Diastolic blood pressure	00					
460 mmHg 46 11.3 eGFR 46 11.3 eGFR 60 ml/menit/1.73 m ² 312 76.5 eGFR 60 ml/menit/1.73 m ² 96 23.5 SGOT 50 μ /L 199 48.8 SGOT 50 μ /L 209 51.2 SGPT 50 μ /L 332 81.4 SGPT >70 μ /L 76 18.6 Hemoglobin Hb <10 mg/dl	≥60 mmHq	362	88 7				
eGFR 60 11.0 eGFR 260 ml/menit/1.73 m ² 312 76.5 eGFR 60 ml/menit/1.73 m ² 96 23.5 SGOT 96 23.5 SGOT 50 μ/L 199 48.8 SGOT >50 μ/L 209 51.2 SGPT SGPT 332 81.4 SGPT >70 μ/L 76 18.6 Hemoglobin 10 202 49.5 Platelet count 2150,000/mm ³ 323 79.2 <150,000/mm ³ 85 20.6 Albumin levels 20.6 45.4	<60 mmHg	46	11.3				
GFR ≥ 60 ml/menit/1.73 m ² 312 76.5 eGFR < 60 ml/menit/1.73 m ² 96 23.5 SGOT sGOT 50 SGOT $\le 50 \ \mu/L$ 199 48.8 SGOT $\ge 50 \ \mu/L$ 209 51.2 SGPT SGPT $\le 70 \ \mu/L$ 76 18.6 Hemoglobin Hb $\ge 10 \ mg/dl$ 206 50.5 Hb $\ge 10 \ mg/dl$ 206 50.5 Platelet count $\ge 150.000/mm^3$ 323 79.2 <150,000/mm ³ 85 20.6 Albumin levels ≥ 20.6 4154	eGER		11.0				
GGFR 260 ml/menit/1.73 m ² 96 23.5 SGOT 99 23.5 SGOT 99 51.2 SGOT >50 μ/L 209 51.2 SGPT 70 μ/L 332 81.4 SGPT >70 μ/L 76 18.6 Hemoglobin 10 202 49.5 Platelet count 2150,000/mm ³ 323 79.2 <150,000/mm ³ 85 20.6 Albumin levels 206 32.7	eGER >60 ml/menit/1 73 m ²	312	76 5				
GOT SGOT SGOT SGOT 50 μ/L 199 48.8 SGOT >50 μ/L 209 SGPT SGPT 332 SGPT ≤70 μ/L 332 81.4 SGPT >70 μ/L 76 18.6 Hemoglobin Hb ≥10 mg/dl 206 Hb ≥10 mg/dl 202 49.5 Platelet count ≥150,000/mm³ 323 ≥150,000/mm³ 85 20.6 Albumin levels >25.5	$eGER < 60 \text{ ml/menit/1.73 m}^2$	96	23.5				
SGOT ≤50 µ/L 199 48.8 SGOT ≤50 µ/L 209 51.2 SGPT SGPT ≤70 µ/L 332 81.4 SGPT >70 µ/L 76 18.6 Hemoglobin Hb ≥10 mg/dl 206 50.5 Hb <10 mg/dl 202 49.5 Platelet count ≥150,000/mm ³ 323 79.2 <150,000/mm ³ 85 20.6 Albumin levels	SGOT	00	20.0				
SGOT >50 µ/L 209 51.2 SGPT 332 81.4 SGPT >70 µ/L 76 18.6 Hemoglobin 100 90 Hb >10 mg/dl 206 50.5 Hb <10 mg/dl	SGOT <50 µ/l	199	48.8				
SGPT SGPT SGPT SGPT $\leq 70 \ \mu/L$ 332 81.4 SGPT $> 70 \ \mu/L$ 76 18.6 Hemoglobin Hb $\geq 10 \ mg/dl$ 206 50.5 Hb $\geq 10 \ mg/dl$ 202 49.5 Platelet count 2150,000/mm ³ 323 79.2 <150,000/mm ³ 85 20.6 Albumin levels 20.6	SGOT >50 µ/l	209	51.2				
SGPT ≤70 µ/L 332 81.4 SGPT >70 µ/L 76 18.6 Hemoglobin 1 18.6 Hb ≥10 mg/dl 206 50.5 Hb <10 mg/dl	SGPT	200	01.2				
SGPT >70 µ/L 76 18.6 Hemoglobin 206 50.5 Hb ≥10 mg/dl 202 49.5 Platelet count ≥150,000/mm³ 323 79.2 <150,000/mm³	SGPT ≤70 µ/l	332	81.4				
Hemoglobin 100 Hb ≥10 mg/dl 206 50.5 Hb <10 mg/dl	SGPT >70 µ/l	76	18.6				
Hb ≥10 mg/dl 206 50.5 Hb ≥10 mg/dl 202 49.5 Platelet count ≥150,000/mm³ 323 79.2 <150,000/mm³	Hemoglobin		10.0				
Hb<10 202 49.5 Platelet count ≥150,000/mm³ 323 79.2 <150,000/mm³	$Hb \ge 10 \text{ mg/dl}$	206	50.5				
Iso migra 252 40.0 Platelet count 2150,000/mm³ 323 79.2 <150,000/mm³	Hb < 10 mg/dl	202	49.5				
>150,000/mm³ 323 79.2 <150,000/mm³	Platelet count	202	10.0				
- 150,000/mm ³ 85 20.6 Albumin levels	>150 000/mm ³	323	79.2				
Albumin levels	<150,000/mm ³	85	20.6				
	Albumin levels	00	20.0				
	>3.5 mg/dl	154	37 7				
<3.5 mg/dl 25/ 62.3	<3.5 mg/dl	254	62.3				
RMI	BMI	204	02.5				
$RMI > 18.5 kg/m^2$ 205 50.2	BMI >18.5 kg/m ²	205	50.2				
BMI <18.5 kg//m ² 203 49.8	$BMI < 18.5 \text{ kg//m}^2$	203	49.8				

GCS: Glasgow Coma Scale, BMI: Body mass index.

who had Hb <10 mg/dl. There were at least 206 patients (50.5%) who had Hb >10 mg/dl and 202 patients (49.5%) who had Hb <10 mg/dl. In addition, most of the patients, specifically 323 patients (79.2%) had >150,000 platelet count. Moreover, there were 254 patients (62.3%) who had an albumin value <3.5 mg/dl and 205 patients (50.2%) had a BMI <18.5 kg/m².

The bivariate analysis in this study used Chi-square analysis in which if p < 0.05, the variable would be feasible to be included in the multivariate analysis. From the results of the bivariate analysis, there were eight variables that had a significant correlation with the HIV/ AIDS patients' mortality, namely, GCS <15 (p = 0.000), the ratio of PaO₂/FiO₂ (p = 0.000), hypotension (p = 0.000), eGFR < 60 ml/min/1.73 m² (p = 0.000), platelet count <150.000 mm³ (p = 0.012), albumin level <3.5 mg/dl (p = 0.000), and BMI ≤18.5 kg/m² (p = 0.000). These eight variables would be included in the multivariate analysis to see which variable was dominant in influencing the hospitalized HIV/AIDS patients' mortality.

Multivariate analysis in this study used logistic regression analysis. The multivariate analysis which showed significant independent variables on the HIV/ AIDS patients' mortality in this study was including GCS <15 (OR 11.625), PaO_2/FiO_2 <400 mmHg (OR 7.794), hypotension (OR 6.062), eGFR <60 ml/min/1.73 m² (OR 2.646), and albumin levels <3.5 mg/dl (OR 4.091). These bivariate analysis and multivariate analysis are shown in Table 2.

Table 2: Analysis univariate and multivariate

Variable	Univariate		Multivariate	
	OR (95% CI)	p-value	OR (95% CI)	p-value
GCS <15	11.960 (6.851-20.878)	0.000	11.625 (5.410-24.981)	0.000
PaO ₂ /FiO ₂ <400 mmHg	11.705 (7.114–19.259)	0.000	7.794 (4.063–14.950)	0.000
Hypotension	12.738 (7.259-22.240)	0.000	6.062 (2.980-12.329)	0.000
eGFR <60 ml/min/1.73 m ²	3.317 (2.061-5.340)	0.000	2.646 (1.314-5.328)	0.008
Elevated transaminase	3.216 (2.051-5.043)	0.000	1.824 (0.946-3.516)	0.104
enzyme				
Hemoglobin <10 mg/dl	1.452 (0.952-2.213)	0.082		
Platelet count	1.873 (1.143-3.069)	0.012		
<150,000/mm ³				
Albumin levels <3.5 mg/dl	5.680 (3.274-9.852)	0.000	4.091 (1.846-9.070)	0.001
BMI <18.5 kg/m ²	2.940 (1.891–4.571)	0.000	1.738 (0.919–3.264)	0.078
CCC: Classes Carla D	MI: Deduceren indeu			

SCS: Glasgow Coma Scale, Bivil: Body mas

Discussion

Neurological disorders associated with HIV/ AIDS include central nervous system infections, vascular complications. peripheral neoplasms. neuropathy, and myopathy. Various studies which have been conducted in developing countries showed that most neurological disorders occurred due to the opportunistic infections [14]. The most frequently used parameter for measuring the impaired central nervous system function is the GCS, which is a neurological scale that aims to assess a person's consciousness. Parameters of organ function disorders, such as APACHE II and SOFA score, classify the central nervous system dysfunction if the GCS is <15 [15].

In this study, GCS <15 was a very significant variable on the hospitalized HIV/AIDS patients' mortality (OR 1.625; CI 95% 5.410–24.981; p = 0.000). The results of this study supported previous study's result in which the patients with GCS <15 had death risk of 7.84 times higher (95% CI 2.03–30.27) [16], [17]. The rate resulted from the previous study was lower than the research we conducted. This could be caused by the differences of the study subjects' characteristics.

Respiratory system disorders are complications which are often found in HIV/AIDS patients and cause morbidity as well as mortality. The mechanism of HIV in causing respiratory system disorders, which in this case is lung damage, is related to systemic and lungs inflammation. Other factors which also play a role in causing lung damage are direct HIV infection to the lungs, smoking, and the effect of ARVs on lung toxicity [18]. PaO₂/FiO₂ ratio is an indicator of respiratory disorders, which in this study referred to the limit according to the SOFA score. In this study, PaO₂/FiO₂ ratio had a significant correlation with the mortality of HIV/AIDS patients with an OR 7.794 (95% CI 4.063-14.950). A study using the PaO₂/FiO₂ ratio was also conducted by Chiliza et al. in which the subjects were HIV patients with PCP infection. In this study, the PaO₂/FiO₂ ratio was considered as a significant predictor of mortality (HR 3.8; 95% CI 1.68.9; p = 0.0030) [19]. Likewise, the similar result was also found in a study conducted by Wu et al., in which PaO₂ <70 as one of the mortality predictors had an HR of 7.328 (95% CI 3.621-14.830) on HIV/AIDS patients' mortality [20].

Cardiovascular dysfunction in HIV/AIDS patients can be caused by direct viral mechanisms, opportunistic infections, and the use of ART [21]. The mechanism of the HIV virus in causing myocardial damage remains unclear. However, it is suspected that there are changes in the function of Th lymphocytes which then cause severe inflammation of the myocardium [22]. Opportunistic infections caused by Toxoplasma gondii, Mycobacterium tuberculosis, and Cryptococcus neoformans are common in AIDS mvocarditis [23]. Treatment with ARVs, especially for the NRTI group, causes a lot of cardiomyopathy through mitochondrial damage which eventually causes myocardial dilatation and dysfunction. Moreover, hypotension is a condition that occurs due to impaired cardiovascular function. This condition indicates the decreasing of cardiac output which can lead to impaired tissue perfusion [24]. This study found that hypotension correlated significantly with the mortality of HIV/AIDS patients by which an OR of 6.062 (95% CI OR 2.980-12.329). These results supported previous research conducted by Bloomfield et al. which resulted IR value of 5.2 (CI 95% 4.8-5.7) [25].

HIV-infected patients have a higher risk of developing kidney disease, terminal renal failure, and death due to kidney disease. A study carried out on 306 HIV/ AIDS patients in China found that the prevalence of kidney problems experienced by hospitalized HIV/AIDS patients reached 5.56% [26]. Disruption of kidney function in HIV/ AIDS-infected patients can be caused by acute kidney failure, HIV-associated nephropathy, and the presence of comorbid chronic kidney disease [27]. Multivariate analysis done in this study showed that impaired renal function had a significant correlation to HIV/AIDS patients' mortality with an OR 2.646 (95% CI 1.314-5.328). This study supported the research conducted in Jakarta [6] as well as the research conducted by Wvatt et al. However, there was a slight difference between the result of this study and a study conducted by Wyatt et al. Categorized into acute renal failure and chronic kidney disease, Wyatt et al study stated that acute renal failure (OR=5.84; 95% CI 5.11-6.65) possessed higher mortality risk compared to chronic kidney disease (OR=1.97%; 95% CI 1.59-2.45) [28].

Reduced glomerular filtration rate is associated with the increasing of cardiovascular events causing mortality in general population. In populations with decreased glomerular filtration, there was an increase in apolipoprotein B and a decrease in apolipoprotein A1, which is a risk factor for coronary heart disease. It was also found that there was an increase in fibrinogen and homocysteine, as well as C-reactive protein which is associated with atherosclerosis. The atherosclerosis itself can increase the risk of cardiovascular disease in the decreased glomerular filtration population [29]. The decreasing of erythropoietin hormone can cause anemia which then results in increasing the endothelial activation and left ventricular hypertrophy. This condition can increase the cardiovascular risk which leads to morbidity and mortality [30]. Disorders of electrolytes or acid base and fluid retention in impaired kidney function can also increase the mortality risk [6].

Several studies have also tried to find a correlation between low albumin levels and mortality in HIV/AIDS patients. Some have found that hypoalbuminemia could be an independent predictor of HIV/AIDS patients' mortality. Low albumin levels (<3.5 g/ dl) are associated with the progression of HIV patients to AIDS [8], [28]. In subjects with CD4 <200 who had albumin levels <3.5 g/dl, the mortality rate was 8 times higher than those with albumin levels > 3.5 g/d [8]. Research on the correlation between serum albumin and mortality in HIV/AIDS patients has also been conducted and showed that patients with albumin levels <3.5 g/dl at the beginning of ART therapy had mortality rate 4.53 times higher than the subjects who had albumin levels >3.5 g/dl (95% CI) [31]. In our study, albumin levels <3.5 mg/dl had a significant correlation with the HIV/AIDS patients' mortality (OR 4.091, 95% CI OR 1.846–9.070). Furthermore, receiver operating characteristic (ROC) curve analysis was also performed for the hypoalbuminemia variable. Based on the analysis of the ROC curve, it was found that the area under the curve was 0.751 with p = 0.027. The best cutoff point for albumin level to predict mortality outcome was in the value of 3.02 with sensitivity of 71.7% and specificity of 70.5% (Figure 1).

There were also some variable which showed insignificant result in multivariate analysis, those were platelet count, elevated liver enzymes, and BMI. Platelet count <150,000 mm^3 in HIV/AIDS patients causes mortality, generally due to the occurrence



Figure 1: Receiver operating characteristic curve hypoalbuminemia to predict mortality. The best cutoff point value for albumin level for predicting the mortality outcome was 3.02 with sensitivity of 71.7% and specificity of 70.5%

of impaired central nervous system function which caused by intracranial bleeding characterized by the GCS. Elevated liver enzymes can be associated with mortality generally through the occurrence of acute liver failure causing encephalopathy which eventually leads to impaired central nervous system function which is also characterized by GCS. BMI <18.5 kg/m² can cause mortality due to susceptibility toward hypoalbuminemia associated infection, in which hypoalbuminemia itself showed a significant correlation with HIV/AIDS hospitalized patients' mortality in multivariate analysis.

Conclusion

The mortality percentage of hospitalized HIV/AIDS patients in this study was recorded at the value of 31.1%. Multivariate analysis which showed GCS <15, hypotension, PaO_2/FiO_2 <400 mmHg, eGFR <60 ml/1.73 kg/m², and albumin levels <3.5 mg/dl was found as an independent risk factors for predicting the hospitalized HIV/AIDS patients' mortality. Early intervention on these significant variables is expected to be able to improve the mortality rate of hospitalized HIV/AIDS patients.

Acknowledgments

The author thanks to Inthen Firdausi Wardhani for providing language corrections to this article.

References

- Djoerban Z, Djauzi S. HIV/AIDS di Indonesia in Buku Ajar Ilmu Penyakit Dalam. 6th ed., Vol. 1. Jakarta: Balai Penerbit FKUI; 2015.
- Japiassu AM, Amancio RT, Mesquita EC, Medeiros DM, Bernal HB, Nunes EP, *et al.* Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care. 2010;14(4):R152. https://doi.org/10.1186/cc9221 PMid:20698966
- Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013. Hematol Am Soc Hematol Educ Program. 2013;2013(1):377-81. https://doi.org/10.1182/ asheducation-2013.1.377 PMid:24319207
- Saleri N, Capone S, Pietra V, Iaco G, Del Punta V, Rizzi M, et al. Outcome and predictive factors of mortality in hospitalized HIVpatients in burkina faso. Infection. 2009;37(2):142-7. https://doi. org/10.1007/s15010-008-7406-7 PMid:19169635
- 5. Rubaihayo J, Tumwesigye NM, Konde-lule J, Makumbi F,

Nakku EJ, Wamani H, *et al.* Trends and predictors of mortality among HIV positive patients in the era of highly active antiretroviral therapy in Uganda. Infect Dis Rep. 2015;7(3):66-73. https://doi.org/10.4081/idr.2015.5967 PMid:26500739

- Puspitasari E, Yunihastuti E, Rengganis I, Rumende CM. Prediktor mortalitas pasien HIV/AIDS rawat inap. J Pen Dalam Indones. 2016;3(1):22-8. https://doi.org/10.7454/jpdi.v3i1.29
- Deshwal R, Arora S. Serum alanine aminotransferase elevations in HIV positive patients on antiretroviral therapy in India. J Assoc Phys India. 2019;67(3):67-70.
 PMid:31304710
- Feldman JG, Burns DN, Stephen J, Bacchetti P, Cohen M, Anastos K, *et al.* Serum albumin as a predictor of survival in HIV-infected women in the women's interagency HIV study. AIDS. 2000;14(7):863-70. https://doi. org/10.1097/00002030-200005050-00013 PMid:10839595
- Hu W, Jiang H, Chen W, He S, Deng B, Wang W. Malnutrition in hospitalized people living with HIV/AIDS : Evidence from a cross-sectional study from Chengdu, China. Asia Pac J Clin Nutr. 2011;20(4):544-50.
 PMid:22094839
- Ibrahim F, Hamzah L, Jones R. Baseline kidney function as predictor of mortality and kidney disease progression in HIVpositive patients. Am J Kidney Dis. 2012;60(4):539-47. https:// doi.org/10.1053/j.ajkd.2012.03.006
 PMid:22521282
- Dusingize JC, Hoover DR, Shi Q, Mutimura E, Rudakemwa E, Ndacyayisenga V, *et al*. Association of abnormal liver function parameters with HIV serostatus and CD4 count in antiretroviralnaïve rwandan women. AIDS Res Hum Retroviruses. 2015;31(7):723-30. https://doi.org/10.1089/aid.2014.0170 PMid:25924728
- Owiredu WK, Quaye L, Amidu N, Addai-Mensah O. Renal insufficiency in Ghanaian HIV infected patients: Need for dose adjustment. Afr Health Sci. 2013;13(1):101-11. https://doi. org/10.4314/ahs.v13i1.14
 PMid:23658575
- Mocroft A, Ryom L, Reiss P, Furrer H, Monforte AD, Gatell J, et al. A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the chronic kidney disease epidemiology collaboration estimating equations in HIV infection. HIV Med. 2014;15(3):144-52. https://doi.org/10.1111/hiv.12095 PMid:24118916
- Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous system infections in individual with HIV-1 infection. J Neurovirol. 2002;8(3):158-67. https://doi.org/10.1080/13550280290049723 PMid:12053271
- Grmec S, Gasparovic V. Comparison of APACHE II, MEES and Glasgow coma scale in patients with nontraumatic coma for prediction of mortality. Crit Care. 2000;5(1):19-23. https://doi. org/10.1186/cc973
 PMid:11178221
- Lee Y, Wang J, Sun H, Chen Y. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect 2011;44(5):338-45. https://doi.org/10.1016/j. jmii.2010.08.011 PMid:21524972
- Pecego AC. Amancio RT, Ribeiro C, Mesquita EC, Medeiros DM, Cerbino J, *et al*. Six-month survival of critically ill patients with HIV--related disease and tuberculosis: A retrospective study. BMC Infect Dis. 2016;6:270. https://doi.org/10.1186/ s12879-016-1644-6

 Cribbs SK, Crothers K, Morris A. Pathogenesis of HIVrelated lung disease: Immunity, infection, and inflammation. Physiol Rev. 2020;100(2):603-32. https://doi.org/10.1152/ physrev.00039.2018

PMid:31600121

 Chiliza N, Du Toit M, Wasserman S. Outcomes of HIV-associated pneumocystis pneumonia at a South African referral hospital. PLoS One. 2018;13(8):e0201733. https://doi.org/10.1371/ journal.pone.0201733

PMid:30071089

 Wu L, Zhang S, Wang Y, Hao Y, Wang F, Gao G, et al. A model to predict in-hospital mortality in HIV/AIDS patients with pneumocystis pneumonia in China: The clinical practice in real world. Biomed Res Int 2019;2019:6057028. https://doi. org/10.1155/2019/6057028

PMid:30906778

21. Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart. 2009;95(14):1193-202. https://doi.org/10.1136/ hrt.2008.161463

PMid:19564432

- Moroni M, Antinori S. HIV and direct damage of organs: Disease spectrum before and during the highly active antiretroviral therapy era. AIDS. 2003;17(1):S51-64. https://doi. org/10.1097/00002030-200304001-00008 PMid:12870531
- 23. Ntusi NA. HIV and myocarditis. Curr Opin HIV AIDS. 2017;12(6):561-5. https://doi.org/10.1097/ coh.000000000000416 PMid:28832366
- Cheitlin MD. In: Basow DS, editor. Cardiac Involvement in HIVinfected Patients. 2nd ed. Waltham, MA: UptoDate; 2010.
- 25. Bloomfield GS, Hogan JW, Keter A, Holland TL, Sang E, Kimaiyo S, et al. Blood pressure level impacts risk of death

among HIV seropositive adults in Kenya: A retrospective analysis of electronic health records. BMC Infect Dis. 2014;14:284. https://doi.org/10.1186/1471-2334-14-284 PMid:24886474

- 26. Sun C, Wen Y, Liu S, Cui W, Zhou Y, Deng, B, *et al.* Prevalence of ginjal impairment among HIV positive patients hospitalized in the first hospital of China medical university. Int J Clin Exp Med. 2018;11(8):8622-862.
- Wyatt CM. Kidney disease and HIV infection. Top Antivir Med. 2017;25(1):13-6.
 PMid:28402929
- Wyatt CM, Klotman PE, Bronfman S, D'Agati VD. HIV-associated nephropathy: Clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol. 2008;28(6):513-22. https://doi.org/10.1016/j.semnephrol.2008.08.005 PMid:19013322
- Munthner P, Hamm L, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140(1):9-17. https://doi. org/10.7326/0003-4819-140-1-200401060-00006 PMid:14706967
- George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1 infected patients. AIDS. 2010;24(3):387-94. https://doi. org/10.1097/qad.0b013e3283359253
 PMid:20019575
- Sudfeld CR, Isanaka S, Aboud S, Mugusi FM, Wang M, Chalamilla GE, *et al.* Association of serum albumin concentration with mortality, morbidity, CD4 T-cell reconstitution among tanzanians initiatin antiretroviral therapy. J Infect Dis. 2013;207(9):1370-8.

PMid:23319741